INTRODUCTION: Our objective is to assess differences in practice patterns and outcomes across 3 regions in bladder cancer patients treated with radical cystectomy under a universal healthcare system. METHODS: In total, we included 2287 patients treated with radical cystectomy at 8 Canadian centres from 1998 to 2008. Variables included various clinico-pathologic parameters, recurrence, and death stratified into different regions. RESULTS: In total, 1105 patients were from the east region (group 1), 601 from the centre region (group 2), and 581 from the west region of Canada (group 3). The median follow-up of groups 1, 2, and 3 was 22.1, 17.1, and 28.6 months, respectively. Although the overall rate of neoadjuvant chemotherapy was low (3.1%), rates were higher in group 2 compared with groups 1 and 3 (p = 0.07). Continent diversions and extended lymphadenectomy were performed in 23.5%, 8.5%, 23.9% and 39.7%, 27.7%, 12.6% across groups 1, 2, and 3, respectively. There were statistically significant differences in gender distribution, performance of lymphadenectomy, presence of concomitant carcinoma in situ and lymphovascular invasion across the 3 groups. There were no differences among the 3 geographical locations in terms of stage, surgical margin status, and use of adjuvant chemotherapy. The mean number of days from the transurethral resection of the bladder tumour to cystectomy was 50, 79, 69 days for groups 1, 2, 3, respectively (p = 0.0006). The 5-year overall survival was 53.6%, 66.8%, and 52.4% for groups 1, 2 and 3, respectively (p < 0.0001). CONCLUSIONS: Significant variations in practice patterns were noted across different geographic regions in a universal healthcare system. Use of continent diversions, extended lymphadenectomy, and neoadjuvant chemotherapy remains low across all 3 regions. Treatment delays are significant.
INTRODUCTION: Our objective is to assess differences in practice patterns and outcomes across 3 regions in bladder cancerpatients treated with radical cystectomy under a universal healthcare system. METHODS: In total, we included 2287 patients treated with radical cystectomy at 8 Canadian centres from 1998 to 2008. Variables included various clinico-pathologic parameters, recurrence, and death stratified into different regions. RESULTS: In total, 1105 patients were from the east region (group 1), 601 from the centre region (group 2), and 581 from the west region of Canada (group 3). The median follow-up of groups 1, 2, and 3 was 22.1, 17.1, and 28.6 months, respectively. Although the overall rate of neoadjuvant chemotherapy was low (3.1%), rates were higher in group 2 compared with groups 1 and 3 (p = 0.07). Continent diversions and extended lymphadenectomy were performed in 23.5%, 8.5%, 23.9% and 39.7%, 27.7%, 12.6% across groups 1, 2, and 3, respectively. There were statistically significant differences in gender distribution, performance of lymphadenectomy, presence of concomitant carcinoma in situ and lymphovascular invasion across the 3 groups. There were no differences among the 3 geographical locations in terms of stage, surgical margin status, and use of adjuvant chemotherapy. The mean number of days from the transurethral resection of the bladder tumour to cystectomy was 50, 79, 69 days for groups 1, 2, 3, respectively (p = 0.0006). The 5-year overall survival was 53.6%, 66.8%, and 52.4% for groups 1, 2 and 3, respectively (p < 0.0001). CONCLUSIONS: Significant variations in practice patterns were noted across different geographic regions in a universal healthcare system. Use of continent diversions, extended lymphadenectomy, and neoadjuvant chemotherapy remains low across all 3 regions. Treatment delays are significant.
Authors: Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes Journal: Eur Urol Date: 2011-03-23 Impact factor: 20.096
Authors: Matthias May; Edwin Herrmann; Christian Bolenz; Arne Tiemann; Sabine Brookman-May; Hans-Martin Fritsche; Maximilian Burger; Alexander Buchner; Christian Gratzke; Christian Wülfing; Lutz Trojan; Jörg Ellinger; Derya Tilki; Christian Gilfrich; Thomas Höfner; Jan Roigas; Mario Zacharias; Sven Gunia; Wolf F Wieland; Markus Hohenfellner; Maurice S Michel; Axel Haferkamp; Stefan C Müller; Christian G Stief; Patrick J Bastian Journal: Eur Urol Date: 2011-01-28 Impact factor: 20.096
Authors: Shahrokh F Shariat; Pierre I Karakiewicz; Guilherme Godoy; Jose A Karam; Raheela Ashfaq; Yves Fradet; Hendrik Isbarn; Francesco Montorsi; Claudio Jeldres; Patrick J Bastian; Matthew E Nielsen; Stefan C Müller; Arthur I Sagalowsky; Yair Lotan Journal: Clin Cancer Res Date: 2009-11-10 Impact factor: 12.531
Authors: Özer Makay; Beyza Özçınar; Turgay Şimşek; Cumhur Arıcı; Bülent Güngör; Serdar Özbaş; Tamer Akça; Ali Uğur Emre; Güldeniz Karadeniz Çakmak; Müfide Akçay; Bülent Ünal; Mustafa Girgin; Sadullah Girgin; Semih Görgülü; Atakan Sezer; Adem Karataş; İbrahim Ali Özemir; Nihat Aksakal; Serap Erel; M Ümit Uğurlu; Ali İlker Filiz; Can Atalay; Ali Uzunköy; Uğur Deveci; Çetin Kotan; Gökhan İçöz; Yavuz Kurt; Abut Kebudi; N Zafer Cantürk; Yeşim Erbil; Rumen Pandev; Bahadır M Güllüoğlu Journal: Balkan Med J Date: 2017-01-05 Impact factor: 2.021
Authors: Alaa Mokhtar; Mohamed Matar Al; Waleed Mohamad Al; Khalid Al Othman; Said A Kattan; Mohammed Faihan Al Journal: Ann Saudi Med Date: 2017 May-Jun Impact factor: 1.526
Authors: Bartosz Dybowski; Krzysztof Ossoliński; Anna Ossolińska; Michał Peller; Ewa Bres-Niewada; Piotr Radziszewski Journal: Cent European J Urol Date: 2015-10-15